Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2

British Journal of Clinical Pharmacology

Volumn 43, Issue 6, 1997, Pages 619-626

  Ball, Simon E ^a   Ahern, Dennis ^a   Scatina, Joann ^a   Kao, John ^a  

^a PFIZER INC   (United States)

Author keywords

CYP2D6; Fluoxetine; Fluvoxamine; Human liver microsomes; Paroxetine; Sertraline; Tricyclic antidepressants; Venlafaxine

Indexed keywords

2 HYDROXYDESIPRAMINE; 2 HYDROXYIMIPRAMINE; CYTOCHROME P450; DESIPRAMINE; ETHOXYRESORUFIN DEETHYLASE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; O DEMETHYLASE; OXYGENASE; PAROXETINE; RESORUFIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; TOLBUTAMIDE; VENLAFAXINE;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

EID: 0030834105     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00591.x     Document Type: Article

References (41)

1. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23: 349-359.
2. Muth EA, Moyer JA, Haskins JT, Andrea TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of WY-45233 and other identified metabolites of the antidepressant venlafaxine. Drugs Dev Res 1991; 23: 191-199.
3. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-156.
4. Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-287.
5. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33: 521-523.
6. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: In vitro and in vivo findings and their implications for patient care. Psycopharmacol Bull 1994; 30: 251-259.
7. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochrome P450. J Pharmacol Exp Ther 1993; 266: 964-971.
8. Fuller RW, Wong DT, Robertson DW. Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev 1990; 11: 17-34.
9. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: Clinical pharmacology and physiological disposition. J Clin Psychiatry 1985; 46: 14-19.
10. Brosen K, Skelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6-the source of the sparteine/ debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991; 32: 136-137.
11. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14: 90-98.
12. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44: 349-355.
13. Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993; 71: 1002-1009.
14. Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA. Serious adverse affects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 1990; 147: 532.
15. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
16. Brosen K, Skelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
17. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151-159.
18. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 1991; 6: 460-462.
19. Lake B. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. In Biochemical Toxicology: A practical approach eds Snell K, Mullock B, IRL Press, England 1987; 183-215.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
21. Omura T, Sato R. The carbon-monoxide binding pigment of liver microsomes. J Biol Chem 1964; 239: 2370-2378.
22. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256-261.
23. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55: 170-171.
24. Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 1974; 137: 143-144.
25. Pelkonen O, Pasanen M, Kuha H, et al. The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other mono-oxygenase activities in human liver: analysis with monclonal antibodies. Br J Clin Pharmacol 1986; 22: 125-134.
26. Murray BP, Lennox SV, Murray S, Boobis AR. Potent in vitro inhibition of human CYP1A2 by pharmacologically diverse agents. Br J Clin Pharmacol 1992; 33: 233P-234P.
27. Cambell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Disp 1987; 15: 237-249.
28. Maenpaa J, Pelkonen O, Cresteil T, Rane A. The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benphetamine in adult and fetal liver. J Steroid Biochem Mol Biol 1993; 44: 61-67.
29. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-299.
30. Burke MD, Mayer RT. Ethoxyresorufin: Direct fluorimetric assay of microsomal O-dealkylation, which is preferentially inducible by 3- methycholanthrene. Drug Metab Dispos 1974; 2: 583-588.
31. Van Der Hoeven T. Assay of hepatic microsomal testosterone hydroxylases by high performance liquid chromatography. Anal Biochem 1984; 138: 57-65.
32. Von Moltke L, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278-1283.
33. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The affect of selective serotonin reuptake inhibitors on cytochrome P-450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-265,
34. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P-450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401-409.
35. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239-248.
36. Spina E, Gampo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992; 14: 194-196.
37. Klamerus KJ, Maloney K, Rudolph R, Sisenwine SF, Jusko WJ, Chaing ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-724.
38. Goodnick PJ. Pharmacokinetics of second-generation antidepressants: fluoxetine. Psycopharmacol Bull 1991; 27: 503-512.
39. Doogan DP, Gaillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49(suppl): 46-51.
40. El-Yazigi A, Chaleby K, Gad A, Raines DA. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 1995; 35: 17-21.
41. Preskorn, S.H. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J Clin Psychiatry 1993; 54: 9(Suppl.).